Open Label Study of OTO-104 in Subjects With Meniere's Disease
NCT02740387
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
34
Enrollment
INDUSTRY
Sponsor class
Stopped
Negative Efficacy Results from the recently completed Phase 3 study 104-201506
Conditions
Meniere's Disease
Interventions
DRUG:
OTO-104
Sponsor
Otonomy, Inc.